Fundamentals and stats

Key facts

—

About

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE and Dual Targeting TriKE platforms. Its product candidates include GTB-3650, a CD33-targeted therapy for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, and GTB-5550, a B7-H3-targeted therapy for solid tumors. The company was founded in 1965 and is headquartered in San Francisco, CA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

GTBP has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company